These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 31065733)
1. First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients. Janikova A; Chloupkova R; Campr V; Klener P; Hamouzova J; Belada D; Prochazka V; Pytlik R; Pirnos J; Duras J; Mocikova H; Bortlicek Z; Kopalova N; Mayer J; Trneny M Ann Hematol; 2019 Aug; 98(8):1961-1972. PubMed ID: 31065733 [TBL] [Abstract][Full Text] [Related]
2. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry. Ellin F; Landström J; Jerkeman M; Relander T Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130 [TBL] [Abstract][Full Text] [Related]
3. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue. Hagemeister FB Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984 [TBL] [Abstract][Full Text] [Related]
4. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Schmitz N; Truemper L; Bouabdallah K; Ziepert M; Leclerc M; Cartron G; Jaccard A; Reimer P; Wagner E; Wilhelm M; Sanhes L; Lamy T; de Leval L; Rosenwald A; Roussel M; Kroschinsky F; Lindemann W; Dreger P; Viardot A; Milpied N; Gisselbrecht C; Wulf G; Gyan E; Gaulard P; Bay JO; Glass B; Poeschel V; Damaj G; Sibon D; Delmer A; Bilger K; Banos A; Haenel M; Dreyling M; Metzner B; Keller U; Braulke F; Friedrichs B; Nickelsen M; Altmann B; Tournilhac O Blood; 2021 May; 137(19):2646-2656. PubMed ID: 33512419 [TBL] [Abstract][Full Text] [Related]
5. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation. Gkotzamanidou M; Papadimitriou CA Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060 [TBL] [Abstract][Full Text] [Related]
6. Up-front Therapy With CHOP Plus Etoposide in Brazilian nodal PTCL Patients: Increased Toxicity and No Survival Benefit Compared to CHOP Regimen-Results of a Real-Life Study From a Middle-Income Country. Lage LAPC; Brito CV; Barreto GC; Culler HF; Reichert CO; Levy D; Costa RO; Zerbini MCN; Rocha V; Pereira J Clin Lymphoma Myeloma Leuk; 2022 Nov; 22(11):812-824. PubMed ID: 35869020 [TBL] [Abstract][Full Text] [Related]
7. Impact of etoposide and ASCT on survival among patients aged <65 years with stage II to IV PTCL: a population-based cohort study. Brink M; Meeuwes FO; van der Poel MWM; Kersten MJ; Wondergem M; Mutsaers PGNJ; Böhmer LH; Woei-A-Jin FJSH; Visser O; Oostvogels R; Jansen PM; Plattel W; Huls GA; Vermaat JSP; Nijland M Blood; 2022 Sep; 140(9):1009-1019. PubMed ID: 35544601 [TBL] [Abstract][Full Text] [Related]
8. Peripheral T-cell lymphomas: analysis of histology, staging and response to treatment of 208 cases at a single institution. Broussais-Guillaumot F; Coso D; Belmecheri N; Ivanov V; Schiano de Collela JM; Aurran-Schleinitz T; Stoppa AM; Chetaille B; Xerri L; Esterni B; Blaise D; Bouabdallah R Leuk Lymphoma; 2013 Nov; 54(11):2392-8. PubMed ID: 23410100 [TBL] [Abstract][Full Text] [Related]
9. Prognosis of patients with peripheral T cell lymphoma who achieve complete response after CHOP/CHOP-like chemotherapy without autologous stem cell transplantation as an initial treatment. Kitahara H; Maruyama D; Maeshima AM; Makita S; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Terauchi T; Kurihara H; Taniguchi H; Komatsu N; Tobinai K Ann Hematol; 2017 Mar; 96(3):411-420. PubMed ID: 27928587 [TBL] [Abstract][Full Text] [Related]
10. High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis. Gui L; Shi YK; He XH; Lei YH; Zhang HZ; Han XH; Zhou SY; Liu P; Yang JL; Dong M; Zhang CG; Yang S; Qin Y Int J Hematol; 2014 Jan; 99(1):69-78. PubMed ID: 24258711 [TBL] [Abstract][Full Text] [Related]
11. Role of frontline autologous stem cell transplantation in young, high-risk diffuse large B-cell lymphoma patients. Yoon JH; Kim JW; Jeon YW; Lee SE; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Park CW; Cho SG Korean J Intern Med; 2015 May; 30(3):362-71. PubMed ID: 25995667 [TBL] [Abstract][Full Text] [Related]
12. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience. Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648 [TBL] [Abstract][Full Text] [Related]
13. First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation. Wilhelm M; Smetak M; Reimer P; Geissinger E; Ruediger T; Metzner B; Schmitz N; Engert A; Schaefer-Eckart K; Birkmann J Blood Cancer J; 2016 Jul; 6(7):e452. PubMed ID: 27471868 [TBL] [Abstract][Full Text] [Related]
14. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556 [TBL] [Abstract][Full Text] [Related]
15. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562 [TBL] [Abstract][Full Text] [Related]
16. Analysis of clinical characteristics and prognosis of patients with peripheral T-cell lymphoma. Liang X; Guo L; Hu X; Li S; Wen S Medicine (Baltimore); 2021 Apr; 100(13):e25194. PubMed ID: 33787601 [TBL] [Abstract][Full Text] [Related]
17. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant. Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455 [TBL] [Abstract][Full Text] [Related]
18. [Influence of transplantation and some clinical factors on prognosis of patients with diffuse large B-cell lymphoma]. Zhao SX; Han Y; Zhu Q; Wang Q; Zhang WJ; Chen XC; Sun AN; Jin ZM; Qiu HY; Tang XW; Fu ZZ; He GS; Miao M; Ma X; Wu DP Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):623-7. PubMed ID: 23815910 [TBL] [Abstract][Full Text] [Related]
19. A retrospective analysis of peripheral T-cell lymphoma treated with the intention to transplant in the first remission. Mehta N; Maragulia JC; Moskowitz A; Hamlin PA; Lunning MA; Moskowitz CH; Zelenetz A; Matasar MJ; Sauter C; Goldberg J; Horwitz SM Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):664-70. PubMed ID: 24035712 [TBL] [Abstract][Full Text] [Related]
20. Results of a phase III clinical trial: CHOP versus CMED in peripheral T-cell lymphoma unspecified. Avilés A; Castañeda C; Neri N; Cleto S; Talavera A; González M; Huerta-Guzmán J; Nambo MJ Med Oncol; 2008; 25(3):360-4. PubMed ID: 18247163 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]